Providing pork producers with the latest production information has long been a World Pork Expo goal. As part of that information sharing, Boehringer Ingelheim Vetmedica, Inc. will sponsor three of the producer education sessions on Thursday, June 7, to address two of the industry’s most pressing issues: production costs and disease management. WPX will be held this year from June 7-9 in Des Moines, Iowa, at the Iowa State Fair Grounds.
At 1 p.m., on Thursday Dennis DiPietre, economist, will provide an outlook on production costs and how producers can prioritize various input costs in order to maintain profit levels.
At 1:40 p.m., Tom Gillespie, veterinarian with Rensselaer Swine Services in Rensselaer, Ind., will discuss porcine respiratory and reproductive syndrome management and its impact on porcine circovirus associated disease.
At 2:20 p.m., Tom Painter, professional services veterinarian with BIVI will address the impact of ileitis on herd health and production profitability.
“Swine disease management and production economics continue to be two of the most important issues facing producers, especially with the tremendous impact that diseases such as PRRS and porcine circovirus type 2 have on profitability,” says Colin Meyers, executive director, food animal business for BIVI.. “We’re pleased to work with the World Pork Expo organizers to bring these timely, highly informative sessions to producers.”
The producer education sessions will be held in the cattle barn sale arena on the Iowa State Fair Grounds. More information on the education sessions and other activities during the 2007 World Pork Expo is available at www.worldpork.org.
Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, Mo.), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, Ct., and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and approximately 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2006, Boehringer Ingelheim posted net sales of US $13.3 billion (10.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information on BIVI, please visit: www.bi-vetmedica.com.
Source: BIVI, WPX